A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases

Biochemistry

Volumn 51, Issue 12, 2012, Pages 2390-2406

  Huang, Yulin ^a,b   Rizzo, Robert C ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b Stony Brook University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COULOMBIC INTERACTIONS; FREE-ENERGY CALCULATIONS; HIGH AFFINITY; HOMOLOGY MODELING; HYDRATION PATTERNS; KINASE INHIBITORS; LAPATINIB; MOLECULAR BASIS; MOLECULAR DYNAMICS SIMULATIONS; QUANTITATIVE AGREEMENT; RECEPTOR TYROSINE KINASE; SIDE-CHAINS; WATER BASED; WATER MOLECULE; WATER NETWORKS;

AMINO ACIDS; HYDRATION; MOLECULAR DYNAMICS;

ENZYMES;

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; LAPATINIB; VASCULOTROPIN RECEPTOR; WATER;

AMINO ACID COMPOSITION; ARTICLE; DRUG BINDING SITE; DRUG MECHANISM; DRUG RESISTANCE; DRUG SPECIFICITY; DRUG STRUCTURE; ENERGY YIELD; HYDRATION; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DYNAMICS; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; BINDING SITES; DRUG DESIGN; DRUG RESISTANCE; HUMANS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE HOMOLOGY, AMINO ACID; SOLVENTS; SUBSTRATE SPECIFICITY; THERMODYNAMICS; WATER;

EID: 84859166733     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi2016553     Document Type: Article

References (83)

1. American Cancer Society: Breast Cancer Facts & Figures 2011-2012. http://www.cancer.org (accessed Oct 26, 2011).
2. Yarden, Y. and Sliwkowski, M. X. (2001) Untangling the ErbB signalling network Nat. Rev. Mol. Cell Biol. 2, 127-137
3. Hynes, N. E. and Lane, H. A. (2005) ERBB receptors and cancer: The complexity of targeted inhibitors Nat. Rev. Cancer 5, 341-354
4. Klijn, J. G. M., Berns, P. M. J. J., Schmitz, P. I. M., and Foekens, J. A. (1992) The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients Endocr. Rev. 13, 3-17
5. Pegram, M. D., Pauletti, G., and Slamon, D. J. (1998) HER-2/neu as a predictive marker of response to breast cancer therapy Breast Cancer Res. Treat. 52, 65-77
6. Drugs@FDA website. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm (accessed Oct 26, 2011).
7. Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., Keith, B. R., Gilmer, T. M., Berger, M., Podratz, K. C., and Slamon, D. J. (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer Res. 66, 1630-1639
8. Blackwell, K. L., Pegram, M. D., Tan-Chiu, E., Schwartzberg, L. S., Arbushites, M. C., Maltzman, J. D., Forster, J. K., Rubin, S. D., Stein, S. H., and Burstein, H. J. (2009) Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens Ann. Oncol. 20, 1026-1031
9. Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., Paulazzo, G., Lyass, L., Trusk, P., Hill, J., Harris, J., and Spector, N. L. (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer Proc. Natl. Acad. Sci. U.S.A. 103, 7795-7800
10. Liu, L., Greger, J., Shi, H., Liu, Y., Greshock, J., Annan, R., Halsey, W., Sathe, G. M., Martin, A.-M., and Gilmer, T. M. (2009) Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL Cancer Res. 69, 6871-6878
11. Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., and Baselga, J. (2008) Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235 Cancer Res. 68, 9221-9230
12. Huang, C., Park, C. C., Hilsenbeck, S. G., Ward, R., Rimawi, M. F., Wang, Y. C., Shou, J., Bissell, M. J., Osborne, C. K., and Schiff, R. (2011) β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib Breast Cancer Res. 13, R84
13. Rexer, B. N., Ham, A. J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., Gonzalez-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., and Arteaga, C. L. (2011) Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition Oncogene 30, 4163-4174
14. Avizienyte, E., Ward, R. A., and Garner, A. P. (2008) Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations Biochem. J. 415, 197-206
15. Trowe, T., Boukouvala, S., Calkins, K., Cutler, R. E., Fong, R., Funke, R., Gendreau, S. B., Kim, Y. D., Miller, N., Woolfrey, J. R., Vysotskaia, V., Yang, J. P., Gerritsen, M. E., Matthews, D. J., Lamb, P., and Heuer, T. S. (2008) EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation Clin. Cancer Res. 14, 2465-2475
16. Rusnak, D. W., Lackey, K., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., and Gilmer, T. M. (2001) The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo Mol. Cancer Ther. 1, 85-94
17. Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., Alligood, K. J., Rusnak, D. W., Gilmer, T. M., and Shewchuk, L. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 64, 6652-6659
18. Zhang, X., Gureasko, J., Shen, K., Cole, P. A., and Kuriyan, J. (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor Cell 125, 1137-1149
19. Stamos, J., Sliwkowski, M. X., and Eigenbrot, C. (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 277, 46265-46272
20. Yun, C. H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., and Eck, M. J. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 11, 217-227
21. Lackey, K. E. (2006) Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor Curr. Top. Med. Chem. 6, 435-460
22. Sartor, C. I., Zhou, H., Kozlowska, E., Guttridge, K., Kawata, E., Caskey, L., Harrelson, J., Hynes, N., Ethier, S., Calvo, B., and Earp, H. S., III (2001) HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells Mol. Cell. Biol. 21, 4265-4275
23. Barnes, N. L., Khavari, S., Boland, G. P., Cramer, A., Knox, W. F., and Bundred, N. J. (2005) Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast Clin. Cancer Res. 11, 2163-2168
24. Qiu, C., Tarrant, M. K., Choi, S. H., Sathyamurthy, A., Bose, R., Banjade, S., Pal, A., Bornmann, W. G., Lemmon, M. A., Cole, P. A., and Leahy, D. J. (2008) Mechanism of Activation and Inhibition of the HER4/ErbB4 Kinase Structure 16, 460-467
25. Gilmer, T. M., Cable, L., Alligood, K., Rusnak, D., Spehar, G., Gallagher, K. T., Woldu, E., Carter, H. L., Truesdale, A. T., Shewchuk, L., and Wood, E. R. (2008) Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib Cancer Res. 68, 571-579
26. Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., and Varmus, H. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2, e73
27. Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., and Halmos, B. (2005) EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib N. Engl. J. Med. 352, 786-792
28. Bean, J., Riely, G. J., Balak, M., Marks, J. L., Ladanyi, M., Miller, V. A., and Pao, W. (2008) Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma Clin. Cancer Res. 14, 7519-7525
29. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293, 876-880
30. Yun, C. H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. K., Meyerson, M., and Eck, M. J. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U.S.A. 105, 2070-2075
31. Wissner, A., Berger, D. M., Boschelli, D. H., Floyd, M. B., Jr., Greenberger, L. M., Gruber, B. C., Johnson, B. D., Mamuya, N., Nilakantan, R., Reich, M. F., Shen, R., Tsou, H. R., Upeslacis, E., Wang, Y. F., Wu, B., Ye, F., and Zhang, N. (2000) 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors J. Med. Chem. 43, 3244-3256
32. Kamath, S. and Buolamwini, J. (2005) Asp746 to Glycine Change May have a Greater Influence than Cys751 to Serine Change in Accounting for Ligand Selectivity between EGFR and HER-2 at the ATP Site J. Comput.-Aided Mol. Des. 19, 287-291
33. Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. L., Pedersen, K., Smith, D. J., Landolfi, S., Ramon y Cajal, S., Arribas, J., and Baselga, J. (2008) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity Oncogene 28, 803-814
34. Hou, T., Zhu, L., Chen, L., and Xu, X. (2003) Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies J. Chem. Inf. Comput. Sci. 43, 273-287
35. Chen, H. F. (2008) Computational study of the binding mode of epidermal growth factor receptor kinase inhibitors Chem. Biol. Drug Des. 71, 434-446
36. Cavasotto, C. N., Ortiz, M. A., Abagyan, R. A., and Piedrafita, F. J. (2006) In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells Bioorg. Med. Chem. Lett. 16, 1969-1974
37. Liu, B., Bernard, B., and Wu, J. H. (2006) Impact of EGFR point mutations on the sensitivity to gefitinib: Insights from comparative structural analyses and molecular dynamics simulations Proteins 65, 331-346
38. Liu, Y., Purvis, J., Shih, A., Weinstein, J., Agrawal, N., and Radhakrishnan, R. (2007) A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations Ann. Biomed. Eng. 35, 1012-1025
39. Balius, T. E. and Rizzo, R. C. (2009) Quantitative Prediction of Fold Resistance for Inhibitors of EGFR Biochemistry 48, 8435-8448
40. Michel, J., Tirado-Rives, J., and Jorgensen, W. L. (2009) Energetics of Displacing Water Molecules from Protein Binding Sites: Consequences for Ligand Optimization J. Am. Chem. Soc. 131, 15403-15411
41. Daub, H., Specht, K., and Ullrich, A. (2004) Strategies to overcome resistance to targeted protein kinase inhibitors Nat. Rev. Drug Discovery 3, 1001-1010
42. Cozzini, P., Fornabaio, M., Marabotti, A., Abraham, D. J., Kellogg, G. E., and Mozzarelli, A. (2004) Free energy of ligand binding to protein: Evaluation of the contribution of water molecules by computational methods Curr. Med. Chem. 11, 3093-3118
43. Lu, Y., Wang, R., Yang, C.-Y., and Wang, S. (2007) Analysis of Ligand-Bound Water Molecules in High-Resolution Crystal Structures of Protein-Ligand Complexes J. Chem. Inf. Model. 47, 668-675
44. Young, T., Abel, R., Kim, B., Berne, B. J., and Friesner, R. A. (2007) Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding Proc. Natl. Acad. Sci. U.S.A. 104, 808-813
45. de Beer, S. B. A., Vermeulen, N. P. E., and Oostenbrink, C. (2010) The role of water molecules in computational drug design Curr. Top. Med. Chem. 10, 55-66
46. Varghese, J. N., Epa, V. C., and Colman, P. M. (1995) Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase Protein Sci. 4, 1081-1087
47. Ren, J., Esnouf, R., Garman, E., Somers, D., Ross, C., Kirby, I., Keeling, J., Darby, G., Jones, Y., and Stuart, D. 1995, High resolution structures of HIV-1 RT from four RT-inhibitor complexes Nat. Struct. Biol. 2, 293-302
48. Wood, E. R., Shewchuk, L. M., Ellis, B., Brignola, P., and Brashear, R. L. 2008, 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases Proc. Natl. Acad. Sci. U.S.A. 105, 2773-2778
49. Aertgeerts, K., Skene, R., Yano, J., Sang, B. C., Zou, H., Snell, G., Jennings, A., Iwamoto, K., Habuka, N., Hirokawa, A., Ishikawa, T., Tanaka, T., Miki, H., Ohta, Y., and Sogabe, S. (2011) Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein J. Biol. Chem. 286, 18756-18765
50. Sali, A. and Blundell, T. L. (1993) Comparative Protein Modelling by Satisfaction of Spatial Restraints J. Mol. Biol. 234, 779-815
51. Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994) Clustal W: Improving the Sensitivity of Progressive Multiple Sequence Alignment through Sequence Weighting, Position-Specific Gap Penalties and Weight Matrix Choice Nucleic Acids Res. 22, 4673-4680
52. Shen, M.-Y. and Sali, A. (2006) Statistical potential for assessment and prediction of protein structures Protein Sci. 15, 2507-2524
53. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) PROCHECK: A program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 26, 283-291
54. MOE (2008) Chemical Computing Group Inc., Montreal.
55. Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kale, L., and Schulten, K. (2005) Scalable molecular dynamics with NAMD J. Comput. Chem. 26, 1781-1802
56. Case, D. A., Darden, T. A., Cheatham, T. E., III, Simmerling, C. L., and Wang, J., et al. (2004) AMBER8, University of California, San Francisco.
57. Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., and Simmerling, C. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins: Struct., Funct., Bioinf. 65, 712-725
58. Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., and Case, D. A. (2004) Development and testing of a general amber force field J. Comput. Chem. 25, 1157-1174
59. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., and Klein, M. L. (1983) Comparison of Simple Potential Functions for Simulating Liquid Water J. Chem. Phys. 79, 926-935
60. Breneman, C. M. and Wiberg, K. B. (1990) Determining Atom-Centered Monopoles from Molecular Electrostatic Potentials: The Need for High Sampling Density in Formamide Conformational Analysis J. Comput. Chem. 11, 361-373
61. Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., and Robb, M. A., et al. (1998) Gaussian 98, revision A.9, Gaussian Inc., Pittsburgh, PA.
62. Feller, S. E., Zhang, Y., Pastor, R. W., and Brooks, B. R. (1995) Constant pressure molecular dynamics simulation: The Langevin piston method J. Chem. Phys. 103, 4613-4621
63. Ryckaert, J.-P., Ciccotti, G., and Berendsen, H. J. C. (1977) Numerical integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes J. Comput. Phys. 23, 327-341
64. Darden, T., York, D., and Pedersen, L. (1993) Particle mesh Ewald: An N log(N) method for Ewald sums in large systems J. Chem. Phys. 98, 10089-10092
65. Srinivasan, J., Cheatham, T. E., III, Cieplak, P., Kollman, P. A., and Case, D. A. (1998) Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices J. Am. Chem. Soc. 120, 9401-9409
66. Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S. H., Chong, L., Lee, M., Lee, T., Duan, Y., Wang, W., Donini, O., Cieplak, P., Srinivasan, J., Case, D. A., and Cheatham, T. E., III (2000) Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models Acc. Chem. Res. 33, 889-897
67. Strockbine, B. and Rizzo, R. C. (2007) Binding of antifusion peptides with HIVgp41 from molecular dynamics simulations: Quantitative correlation with experiment Proteins: Struct., Funct., Bioinf. 67, 630-642
68. Chachra, R. and Rizzo, R. C. (2008) Origins of Resistance Conferred by the R292K Neuraminidase Mutation via Molecular Dynamics and Free Energy Calculations J. Chem. Theory Comput. 4, 1526-1540
69. Carrascal, N. and Rizzo, R. C. (2009) Calculation of binding free energies for non-zinc chelating pyrimidine dicarboxamide inhibitors with MMP-13 Bioorg. Med. Chem. Lett. 19, 47-50
70. McGillick, B. E., Balius, T. E., Mukherjee, S., and Rizzo, R. C. (2010) Origins of Resistance to the HIVgp41 Viral Entry Inhibitor T20 Biochemistry 49, 3575-3592
71. Onufriev, A., Bashford, D., and Case, D. A. (2004) Exploring protein native states and large-scale conformational changes with a modified generalized born model Proteins: Struct., Funct., Bioinf. 55, 383-394
72. Sitkoff, D., Sharp, K. A., and Honig, B. (1994) Accurate Calculation of Hydration Free-Energies Using Macroscopic Solvent Models J. Phys. Chem. 98, 1978-1988
73. Grossfield, A. and Zuckerman, D. M. (2009) Quantifying uncertainty and sampling quality in biomolecular simulations Annu. Rep. Comput. Chem. 5, 23-48
74. Hess, B. (2002) Determining the shear viscosity of model liquids from molecular dynamics simulations J. Chem. Phys. 116, 209-217
75. Spackova, N., Cheatham, T. E., III, Ryjacek, F., Lankas, F., Van Meervelt, L., Hobza, P., and Sponer, J. (2003) Molecular dynamics simulations and thermodynamics analysis of DNA-drug complexes. Minor groove binding between 4′,6-diamidino-2-phenylindole and DNA duplexes in solution J. Am. Chem. Soc. 125, 1759-1769
76. Masukawa, K. M., Kollman, P. A., and Kuntz, I. D. (2003) Investigation of Neuraminidase-Substrate Recognition Using Molecular Dynamics and Free Energy Calculations J. Med. Chem. 46, 5628-5637
77. Wong, S., Amaro, R. E., and McCammon, J. A. (2009) MM-PBSA Captures Key Role of Intercalating Water Molecules at a Protein-Protein Interface J. Chem. Theory Comput. 5, 422-429
78. Liu, Y. and Gray, N. S. (2006) Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2, 358-364
79. Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., and Moasser, M. M. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Nature 445, 437-441
80. Hsieh, A. C. and Moasser, M. M. (2007) Targeting HER proteins in cancer therapy and the role of the non-target HER3 Br. J. Cancer 97, 453-457
81. Garrett, J. T., Olivares, M. G., Rinehart, C., Granja-Ingram, N. D., Sanchez, V., Chakrabarty, A., Dave, B., Cook, R. S., Pao, W., McKinely, E., Manning, H. C., Chang, J., and Arteaga, C. L. (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase Proc. Natl. Acad. Sci. U.S.A. 108, 5021-5026
82. Shi, F., Telesco, S. E., Liu, Y., Radhakrishnan, R., and Lemmon, M. A. (2010) ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation Proc. Natl. Acad. Sci. U.S.A. 107, 7692-7697
83. Jura, N., Shan, Y., Cao, X., Shaw, D. E., and Kuriyan, J. (2009) Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 Proc. Natl. Acad. Sci. U.S.A. 106, 21608-21613